Tesaro, Inc.
Clinical trials sponsored by Tesaro, Inc., explained in plain language.
Oncology biotech acquired by GSK, known for cancer drug Zejula.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill may keep ovarian cancer at bay after chemo
Disease control OngoingThis study tests whether a daily pill called niraparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. About 733 women with stage III or IV ovarian cancer who responded to platinum-based chemo took either niraparib or a placebo. The main goal wa…
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug dostarlimab shows promise in early trial for advanced cancers
Disease control OngoingThis early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug cocktail shows promise in battle against advanced ovarian cancer
Disease control OngoingThis study tests whether adding two newer drugs (dostarlimab and niraparib) to standard chemotherapy helps people with advanced ovarian cancer live longer without their cancer growing. About 1,400 participants with stage III or IV ovarian cancer will receive either the standard t…
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New antibody TSR-022 takes on advanced cancers in first human trial
Disease control OngoingThis study tests a new drug called TSR-022 in people with advanced solid tumors that have not responded to other treatments. The drug is an antibody that targets a protein on immune cells to help fight cancer. The trial has two parts: first, finding the safest dose, and then test…
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Immunotherapy plus chemo shows promise in advanced uterine cancer trial
Disease control OngoingThis phase 3 study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants receive either dostarlimab …
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:51 UTC